Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Neurotech International Ltd

NTI.AX ✓ COMPLIANT ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.01

▲ +7.69%

Market Cap $15.96M · Vol 2.47M

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$15.96M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

33.33

Momentum

Beta

0.95

vs Market

52W High

$0.02

48.09% below

52W Low

$0.01

41.46% above

Volume

2.47M

Avg 1.71M

P/B

5.33

Price-to-book

ROE

N/A

Return on equity

Free Float

76.55%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Neurotech International Ltd (NTI.AX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NTI.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.67%

-17.65%

+27.27%

+7.69%

YTD

+0.00%

-65.33%

-72.00%

Financials & Valuation

TTM · Annual

Total Revenue	$1.70M
Net Income	$-6,974,035.00
Revenue Growth (YoY)	-93.76%
Gross Margin	100.00%
Operating Margin	-410.57%
Net Profit Margin	-410.57%
ROE	N/A
ROA · ROIC	-137.17% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	6.02
P/B	5.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.62B

Technical Indicators

50-Day SMA	$0.01
200-Day SMA	$0.01
RSI (14)	33.33
Beta	0.95
52-Week High	$0.02
52-Week Low	$0.01

Volume Today	2.47M
Avg Daily Volume (30D)	1.71M
Relative Volume	1.45x
Volatility (10D)	102.02
Volatility (30D)	91.90
Free Float	76.55%

Analyst Consensus

N/A

Current Price $0.01

Mean Target N/A

52W Low$0.01 52W High$0.02

Current

Target

$0.01 $0.02

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00DSXRN80

ISINAU000000NTI9

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company focuses predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD). In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved. The Company’s subsidiaries include AAT Research Ltd and AAT Medical Ltd.